SEC Form 4 · accession 0001104659-17-074583
Mersana Therapeutics, Inc. · MRSN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anna Protopapas
Officer — President and CEO · Director
Period of report
Dec 20, 2017
Accepted (ET)
Dec 21, 2017 · 4:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001442836
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 20, 2017 | M | 10,417 | $1.53 | A | 130,719 | D | |
| Common StockF1 | holding | — | — | — | 72,263 | I | By Kinney/Protopapas Family Irrevocable Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF2 | $1.53 | Dec 20, 2017 | M | 10,417 | D | — | May 7, 2025 | Common Stock | 10,417 | 748,366 | D |
Explanation of responses
- F1These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- F2The original option grant for 879,085 option shares vested 25% on March 2, 2016 and in quarterly installments thereafter.